Literature DB >> 1303261

Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome.

S A Smith1, D F Easton, D G Evans, B A Ponder.   

Abstract

A predisposing gene for breast and ovarian cancer has recently been mapped to chromosome 17q12-21. If this gene is a tumour suppressor gene, allele losses would be expected in the tumours of affected family members and the losses should affect the wild-type chromosome, reflecting the need for inactivation of the wild-type allele at the predisposing locus. In four multiple case breast-ovarian cancer families, we have found that in each of nine tumours which showed allele losses, the losses were from the wild-type chromosome. This suggests that the putative 'breast-ovarian' cancer gene is indeed a tumour suppressor gene.

Entities:  

Mesh:

Year:  1992        PMID: 1303261     DOI: 10.1038/ng1092-128

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  101 in total

Review 1.  Functional domains of the BRCA1 and BRCA2 proteins.

Authors:  R Baer; W H Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-10       Impact factor: 2.673

2.  BRCA1 partially reverses the transforming activity of the ras oncogene.

Authors:  A Kumar; C Knott; K Kuus-Reichel; M S Saedi
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 3.  Fine tuning chemotherapy to match BRCA1 status.

Authors:  Melissa Price; Alvaro N A Monteiro
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

Review 4.  A continuum model for tumour suppression.

Authors:  Alice H Berger; Alfred G Knudson; Pier Paolo Pandolfi
Journal:  Nature       Date:  2011-08-10       Impact factor: 49.962

5.  Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites.

Authors:  F Durocher; P Tonin; D Shattuck-Eidens; M Skolnick; S A Narod; J Simard
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

6.  The dependence of the risk of breast cancer in women on their genotype.

Authors:  V A Tarasov; M M Aslanyan; E S Tsyrendorzhieva; R F Gar'kavtseva; L N Lyubchenko; Yu P Altukhov
Journal:  Dokl Biol Sci       Date:  2004 Sep-Oct

7.  Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.

Authors:  Marc Tischkowitz; Nancy Hamel; Marcelo A Carvalho; Gabriel Birrane; Aditi Soni; Erik H van Beers; Simon A Joosse; Nora Wong; David Novak; Louise A Quenneville; Scott A Grist; Petra M Nederlof; David E Goldgar; Sean V Tavtigian; Alvaro N Monteiro; John A A Ladias; William D Foulkes
Journal:  Eur J Hum Genet       Date:  2008-02-20       Impact factor: 4.246

8.  A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

Authors:  Bastiaan Evers; Eva Schut; Eline van der Burg; Tanya M Braumuller; David A Egan; Henne Holstege; Pauline Edser; David J Adams; Richard Wade-Martins; Peter Bouwman; Jos Jonkers
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

Review 9.  Familial breast cancer and genes involved in breast carcinogenesis.

Authors:  A Lindblom
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

10.  Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.

Authors:  O Johannsson; E A Ostermeyer; S Håkansson; L S Friedman; U Johansson; G Sellberg; K Brøndum-Nielsen; V Sele; H Olsson; M C King; A Borg
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.